Results 201 to 210 of about 319,606 (332)

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Prenatal betamethasone–postnatal N‐methyl‐D‐aspartic acid model of spasms: Update on mechanisms and treatments

open access: yesEpilepsia Open, EarlyView.
Abstract Infantile epilepsy spasms syndrome (IESS), formerly known as infantile spasms or West Syndrome, is a severe epilepsy syndrome affecting about 3 in 10,000 newborns in the United States. Characterized by clusters of epileptic spasms, interictal hypsarrhythmia, and developmental delays, IESS has diverse causes, including structural‐metabolic ...
Kayla Vieira   +5 more
wiley   +1 more source

Loss of the Y Chromosome in Oral Potentially Premalignant Disorders Predicts Malignant Progression: An Integrative Cross‐Species Multi‐Cohort Bioinformatic Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The loss of the Y chromosome (LOY) and the extreme down‐regulation of Y chromosome gene expression (EDY) are frequently observed in oral squamous cell carcinoma (OSCC). However, their roles in oral potentially malignant disorders (OPMDs) are unclear.
Rui Han   +6 more
wiley   +1 more source

Comparative transcription map of the wobbler critical region on mouse chromosome 11 and the homologous region on human chromosome 2p13-14 [PDF]

open access: diamond, 2002
Sonja Fuchs   +6 more
openalex   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy